Arelis Cordero-Gomez, MD
Critical Care Medicine · Kissimmee, FLNPI 1437594942
Payments from drug & device makers
Across 593 payments — averaging $32.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$4K
- Covidien LP$2K
- Boehringer Ingelheim$1K
- Jazz Pharmaceuticals Inc.$785
- United Therapeutics Corporation$773
- plus $6K from 32 others
What the payments were for
- Travel & lodging$1,7409%
- Food & beverage$17,46291%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 145 | $4,316 |
| GSK | 175 | $3,697 |
| Covidien LP | 4 | $2,493 |
| Boehringer Ingelheim | 53 | $1,301 |
| Jazz Pharmaceuticals Inc. | 7 | $785 |
| United Therapeutics Corporation | 9 | $773 |
| Grifols USA, LLC | 21 | $729 |
| Regeneron Healthcare Solutions, Inc. | 27 | $623 |
| Actelion Pharmaceuticals US, Inc. | 14 | $529 |
| Sanofi | 18 | $428 |
| Mylan Specialty L.p. | 15 | $344 |
| Insmed, Inc. | 15 | $339 |
| Amgen | 8 | $302 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $279 |
| Verona Pharma, Inc. | 12 | $223 |
| Pulmonx Corporation | 4 | $205 |
| Johnson & Johnson(2 entities) | 4 | $192 |
| Electromed, Inc. | 12 | $187 |
| Axsome Therapeutics, Inc. | 5 | $180 |
| Vapotherm Inc | 2 | $176 |
| Harmony Biosciences LLC | 2 | $170 |
| Philips North America LLC | 6 | $169 |
| Idorsia Pharmaceuticals US Inc | 3 | $140 |
| La Jolla Pharmaceutical Company | 1 | $129 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 2 | $112 |
| Baxter Healthcare | 2 | $54 |
| Lilly USA, LLC | 2 | $39 |
| Novartis | 2 | $37 |
| Ceribell, Inc. | 2 | $31 |
| Merck | 1 | $25 |
| Viatris Specialty LLC | 1 | $23 |
| Pfizer | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Bayer | 1 | $16 |
| AbbVie | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- superDimension$2,493
- BREZTRI$1,029
- FASENRA$907
- NUCALA$716
- XYWAV$504
- AIRSUPRA$426
- FARXIGA$352
- TEZSPIRE$351
- UPTRAVI$259
- OPSUMIT$259
- DUPIXENT$246
- SUNOSI$246
- TRELEGY ELLIPTA$242
- Xembify$152
- Precision Flow$147
- CHARTIS CATHETER$141
- ZEPHYR DELIVERY CATHETER$141
- ZEPHYR ENDOBRONCHIAL VALVE$141
- PULMONX CHARTIS TABLET CONSOLE$141
- GIAPREZA$129
How this compares
$19,239 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 439 | $526,281 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 314 | $326,625 |
| OpsumitMacitentan | 13 | $166,709 |
| NucalaMepolizumab | 42 | $151,948 |
| OfevNintedanib Esylate | 12 | $149,798 |
| Spiriva RespimatTiotropium Bromide | 98 | $106,080 |
| SymbicortBudesonide/Formoterol Fumarate | 144 | $48,779 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $45,244 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $40,197 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $32,729 |
| EliquisApixaban | 19 | $19,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 876 | $18,982 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $14,641 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $13,421 |
| Wixela InhubFluticasone Propion/Salmeterol | 49 | $10,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $3,697 | $778,311611 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $4,316 | $380,494469 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,301 | $288,607146 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $529 | $166,70913 claims |
| PfizerEliquis | $19 | $19,08619 claims |
| MerckDulera | $25 | $6,17812 claims |
| Hikma Pharmaceuticals USAEpinephrine | $17 | $1,73511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Kissimmee
- Fortune AlabiKissimmee$3.2M
- Fred UmehKissimmee$682K
- Maximo LamaKissimmee$255K
- Irtza SharifKissimmee$44K
- Jeffrey LevyHollywood$19M
- Ahmad AswadMiami$6.6M
- George DuvallVero Beach$6M
- Carlos VacaMiami$3M
- Debabrata BandyopadhyayTampa$1.9M
- Christopher HardenGainesville$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.